Ocular Therapeutix, Inc. (OCUL): Price and Financial Metrics
OCUL Price/Volume Stats
| Current price | $5.00 | 52-week high | $11.31 |
| Prev. close | $5.07 | 52-week low | $2.00 |
| Day low | $5.00 | Volume | 1,092 |
| Day high | $5.00 | Avg. volume | 2,106,304 |
| 50-day MA | $8.62 | Dividend yield | N/A |
| 200-day MA | $4.92 | Market Cap | 743.14M |
OCUL Stock Price Chart Interactive Chart >
Ocular Therapeutix, Inc. (OCUL) Company Bio
Ocular Therapeutix is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. The company was founded in 2006 and is based in Bedford, Massachusetts.
Latest OCUL News From Around the Web
Below are the latest news stories about OCULAR THERAPEUTIX INC that investors may wish to consider to help them evaluate OCUL as an investment opportunity.
Ocular Therapeutix™ Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional SharesBEDFORD, Mass., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix™, Inc. (Nasdaq: OCUL) (the “Company”), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the closing of its previously announced underwritten public offering of 35,420,000 shares of its common stock at a public offering price of $3.25 per share, which includes 4,620,000 shares issued upon the exercise in full |
Ocular Therapeutix, Inc.'s (NASDAQ:OCUL) 72% Price Boost Is Out Of Tune With RevenuesOcular Therapeutix, Inc. ( NASDAQ:OCUL ) shareholders would be excited to see that the share price has had a great... |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayIt's time to start the day off right with a look at the biggest pre-market stock movers to watch for Thursday morning! |
Ocular Therapeutix™ Announces Pricing of Public Offering of Common StockBEDFORD, Mass., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix™, Inc. (Nasdaq: OCUL) (the “Company”), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the pricing of an underwritten public offering of 30,800,000 shares of its common stock at a public offering price of $3.25 per share for gross proceeds of $100.1 million, before deducting underwriting discounts and commi |
Ocular Therapeutix™ Announces Proposed Public Offering of Common StockBEDFORD, Mass., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix™, Inc. (Nasdaq: OCUL) (the “Company”), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has commenced an underwritten public offering of its common stock. In addition, the Company is expected to grant the underwriters of the offering a 30-day option to purchase up to an additional 15% of the number o |
OCUL Price Returns
| 1-mo | -47.31% |
| 3-mo | 24.69% |
| 6-mo | 103.25% |
| 1-year | -19.35% |
| 3-year | -67.65% |
| 5-year | 25.31% |
| YTD | 12.11% |
| 2023 | 58.72% |
| 2022 | -59.68% |
| 2021 | -66.33% |
| 2020 | 424.05% |
| 2019 | -0.75% |
Continue Researching OCUL
Want to do more research on Ocular Therapeutix Inc's stock and its price? Try the links below:Ocular Therapeutix Inc (OCUL) Stock Price | Nasdaq
Ocular Therapeutix Inc (OCUL) Stock Quote, History and News - Yahoo Finance
Ocular Therapeutix Inc (OCUL) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...